By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Arch Therapeutics 

1 Chieftain Lane

Natick  Massachusetts  01760  U.S.A.
Phone: 617-475-5254 Fax: n/a




Company News
Arch Therapeutics Announces Favorable Preclinical Data From An Independent Study Of AC5 Surgical Hemostatic Device Versus A Popular Cellulose-Based Hemostatic Agent 3/25/2015 12:00:06 PM
Arch Therapeutics Announces Positive Safety Results For AC5 Surgical Hemostatic Device In Preclinical Toxicity Studies 3/23/2015 11:43:23 AM
Pre-Clinical Animal Pilot Study Shows Arch Therapeutics' AC5(TM) Compared Favorably Versus A Popular Hemostatic Agent 2/23/2015 1:23:09 PM
Nanomedicine: Nanotechnology, Biology, And Medicine Publishes Preclinical Data On Arch Therapeutics' AC5 Surgical Hemostatic Device 2/19/2015 8:54:30 AM
The British Standards Institution Classifies Arch Therapeutics' AC5(TM) As A Medical Device Within The European Union 2/18/2015 11:22:11 AM
Arch Therapeutics Obtains Additional Positive Results For AC5 Surgical Hemostatic Device™ In Preclinical Safety Study 1/13/2015 10:12:13 AM
Arch Therapeutics Announces Positive Results For AC5 Surgical Hemostatic Device™ In Biochemical And Cell Function Safety Studies 1/6/2015 10:30:02 AM
Arch Therapeutics To Present At The Biotech Showcase(TM) 2015 Conference On January 14th 2015 12/18/2014 9:48:56 AM
Arch Therapeutics To Present At LD Micro Main Event On December 4th 2014 11/26/2014 9:31:03 AM
Arch Therapeutics Reports Positive Preclinical Data From Study of AC5 Surgical Hemostatic Device™ In Animals Treated With Brilinta® (ticagrelor) 11/18/2014 1:15:28 PM